⚖️Semaglutide
GLP-1 receptor agonist. FDA-approved (Ozempic/Wegovy). Up to 15% weight loss in Phase III trials. Reduces cardiovascular events (SELECT trial). The benchmark for GLP-1 weight loss research.
GLP-1 analogue with C18 fatty diacid chainWhat Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. FDA-approved as Ozempic (T2D) and Wegovy (obesity). Its C18 fatty diacid chain enables albumin binding, extending half-life to ~7 days for weekly dosing. The SELECT cardiovascular outcomes trial (2023) demonstrated 20% reduction in MACE events in non-diabetic obese adults.
Key Mechanisms
- GLP-1R agonism — hypothalamic appetite suppression (NPY/AgRP inhibition)
- Gastric emptying delay — prolonged satiety duration
- Glucose-dependent insulin secretion — pancreatic β-cell activation
- Cardiovascular protection — reduces inflammation, improves endothelial function
Key References
- Wilding JPH et al. "Semaglutide in Adults with Overweight or Obesity." N Engl J Med, 2021;384:989–1002.
- Lincoff AM et al. "Semaglutide and cardiovascular outcomes in obesity (SELECT)." N Engl J Med, 2023;389:2221–2232.
Frequently Asked Questions
Both are semaglutide — the same active molecule marketed under different brand names and dose schedules for different approved indications (Ozempic for type 2 diabetes, Wegovy for chronic weight management).
It's engineered with a C18 fatty diacid side chain that binds circulating albumin, protecting it from rapid enzymatic degradation (DPP-4) and renal clearance — extending its half-life to roughly a week and enabling once-weekly dosing schedules in research protocols.
It was the first trial to show a GLP-1 agonist reduced major cardiovascular events (MACE) by 20% in non-diabetic obese adults, expanding research interest in semaglutide beyond weight loss and glycaemic control into cardiovascular risk-reduction mechanisms.